Table 3: Adverse events in safety population for hydroxychloroquine prophylaxis randomized control trials.
|
N |
Control |
Hydroxychloroquine |
p-value |
||||
n |
Any adverse event |
n |
Any adverse event |
|||||
Abella, et al. [19] |
130 |
65 |
17 |
26% |
65 |
29 |
45% |
0.03 |
Rajasingham, et al. [18] |
1405 |
469 |
100 |
21% |
936 |
316 |
34% |
< 0.001 |
Mitja, et al. [17] |
2497 |
1300 |
77 |
6% |
1197 |
671 |
56% |
< 0.001 |
Boulware, et al. [16] |
700 |
351 |
59 |
17% |
349 |
140 |
40% |
< 0.001 |
Rajasingham, et al. [18]: Rajasingham results are presented for pooled hydroxychloroquine arms.